Home » Stocks » NuVasive

NuVasive, Inc. (NUVA)

Stock Price: $52.67 USD -1.04 (-1.94%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
After-hours: $53.02 +0.35 (0.67%) Aug 10, 4:11 PM

Stock Price Chart

Key Info

Market Cap 2.70B
Revenue (ttm) 1.06B
Net Income (ttm) -3.83M
Shares Out 51.25M
EPS (ttm) -0.07
PE Ratio n/a
Forward PE 53.19
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $52.67
Previous Close $53.71
Change ($) -1.04
Change (%) -1.94%
Day's Open 54.01
Day's Range 52.65 - 54.15
Day's Volume 647,855
52-Week Range 28.55 - 81.91

More Stats

Market Cap 2.70B
Enterprise Value 3.27B
Earnings Date (est) Nov 3, 2020
Ex-Dividend Date n/a
Shares Outstanding 51.25M
Float 50.85M
EPS (basic) -0.09
EPS (diluted) -0.07
FCF / Share 1.28
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 2.42%
Payout Ratio n/a
Shares Short 6.83M
Short Ratio 8.01
Short % of Float 20.88%
Beta 1.35
PE Ratio n/a
Forward PE 53.19
P/FCF Ratio 41.27
PS Ratio 2.54
PB Ratio 3.02
Revenue 1.06B
Operating Income 63.70M
Net Income -3.83M
Free Cash Flow 65.40M
Net Cash -574.92M
Net Cash / Share -11.22
Gross Margin 80.37%
Operating Margin 5.98%
Profit Margin -0.40%
FCF Margin 6.14%
ROA 1.59%
ROE -0.44%
ROIC 2.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (18)

Buy 8
Overweight 1
Hold 7
Underweight 1
Sell 1

Analyst Consensus: Overweight

Price Target

$65.88*
(25.08% upside)
Low
50.0
Current: $52.67
High
78.0
Target: 65.88
*Average 12-month price target from 17 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1,1681,1021,027962811762685620541478
Revenue Growth6.02%7.31%6.71%18.62%6.39%11.27%10.47%14.75%13.02%-
Gross Profit856791758722617580505467428393
Operating Income12354.1711112413918.1433.0937.00-85.0432.09
Net Income65.2312.4881.6037.1966.29-16.727.903.14-69.8578.29
Shares Outstanding51.9651.3850.8750.0848.6946.7244.4643.3340.3739.25
Earnings Per Share1.230.241.480.691.26-0.360.170.07-1.731.85
EPS Growth412.5%-83.78%114.49%-45.24%--142.86%---
Operating Cash Flow23521917715888.7311697.4413062.9765.83
Capital Expenditures-123-102-110-88.37-75.73-58.18-47.60-41.19-53.37-45.85
Free Cash Flow11211766.7569.7113.0057.3749.8488.899.6019.98
Cash & Equivalents21512078.20161363486365381378185
Total Debt702603583626373361346407394230
Net Cash / Debt-487-482-505-465-9.5412519.41-26.02-15.70-45.42
Assets1,8851,7081,6401,5711,3031,3421,1801,1641,124802
Liabilities970873841870584693575626630368
Book Value915835796695712640596538483422
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name NuVasive, Inc.
Country United States
Employees 2,800
CEO J. Christopher Barry

Stock Information

Ticker Symbol NUVA
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Unique Identifier NASDAQ: NUVA

Description

NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprises products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine to perform restorative and fusion procedures in a minimally disruptive fashion. The company's biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty and gel. Its IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, it offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and Precice, a limb lengthening system. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.